Activated astrocytes: a therapeutic target in Alzheimer’s disease?

References

• Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol. Aging16(3), 271–278 (1995).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid β-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. Neurobiol. Aging23(5), 655–664 (2002).
   PubMed Web of Science ®Google Scholar
• Smith M, Richey Harris P, Sayre L, Beckman J, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J. Neurosci.17(8), 2653–2657 (1997).
   PubMed Web of Science ®Google Scholar
• Halliday G, Robinson S, Shepherd C, Kril J. Alzheimer’s disease and inflammation: a review of cellular and therapeutic mechanisms. Clin. Exp. Pharmacol. Physiol.27(1–2), 1–8 (2000).
   PubMed Web of Science ®Google Scholar
• Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer’s disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol.54(2), 276–281 (1995).
   PubMed Web of Science ®Google Scholar
• Meda L, Cassatella MA, Szendrei GI et al. Activation of microglial cells by β-amyloid protein and interferon-α. Nature374(6523), 647–650 (1995).
   PubMed Web of Science ®Google Scholar
• Pachter JS. Inflammatory mechanisms in Alzheimer disease: the role of β-amyloid/glial interactions. Mol. Psychiatry2(2), 91–95 (1997).
   PubMed Web of Science ®Google Scholar
• Wang D, Bordey A. The astrocyte odyssey. Prog. Neurobiol.86(4), 342–367 (2008).
   PubMed Web of Science ®Google Scholar
• Gavillet M, Allaman I, Magistretti PJ. Modulation of astrocytic metabolic phenotype by proinflammatory cytokines. Glia56(9), 975–989 (2008).
   PubMedGoogle Scholar
• Frederickson R. Astroglia in Alzheimer’s disease. Neurobiol. Aging13(2), 239–253 (1992).
   PubMedGoogle Scholar
• Bouzier-Sore AK, Serres S, Canioni P, Merle M. Lactate involvement in neuron–glia metabolic interaction: 13C-NMR spectroscopy contribution. Biochimie85(9), 841–848 (2003).
   Google Scholar
• Benarroch E. Neuron–astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin. Proc.80, 1326–1338 (2005).
   PubMed Web of Science ®Google Scholar
• Oz G, Seaquist ER, Kumar A et al. Human brain glycogen content and metabolism: implications on its role in brain energy metabolism. Am. J. Physiol. Endocrinal. Metab.292(3), 946–951 (2006).
   Google Scholar
• Pellerin L, Magistretti P. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl Acad. Sci. USA91(22), 10625–10629 (1994).
   PubMed Web of Science ®Google Scholar
• Bittar PG, Charnay Y, Pellerin L, Bouras C, Magistretti PJ. Selective distribution of lactate dehydrogenase isoenzymes in neurons and astrocytes of human brain. J. Cereb. Blood Flow Metab.16(6), 1079–1089 (1996).
   PubMedGoogle Scholar
• Sokoloff L. Measurement of local cerebral glucose utilization and its relation to local functional activity in the brain. Adv. Exp. Med. Biol.291, 21–42 (1991).
   Google Scholar
• Pascual JM, van Heertum RL, Wang D, Engelstald K, De Vivo DC. Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann. Neurol.52(4), 458–464 (2002).
   Google Scholar
• Aubert A, Costalat R. Interaction between astrocytes and neurons studied using a mathematical model of compartmentalized energy metabolism. J. Cereb. Blood Flow Metabol.25(11), 1476–1490 (2005).
   PubMed Web of Science ®Google Scholar
• Magistretti PJ. Cellular bases of functional brain imaging: insights from neuron–glia metabolic coupling. Brain Res.886(1–2), 108–112 (2000).
   PubMed Web of Science ®Google Scholar
• Magistretti P, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Phil. Trans. Biol. Sci.354, 1155–1163 (1999).
   PubMedGoogle Scholar
• Magistretti P, Pellerin L, Rothman D, Shulman R. Energy on demand. Science283(5401), 496–497 (1999).
   PubMed Web of Science ®Google Scholar
• Aubert A, Costalat R, Magistretti PJ, Pellerin L. Brain lactate kinetics: modeling evidence for neuronal lactate uptake upon activation. Proc. Natl Acad. Sci. USA102(45), 16448–16453 (2005).
   PubMed Web of Science ®Google Scholar
• Bernardinelli Y, Magistretti P, Chatton J. Astrocytes generate Na+-mediated metabolic waves. Proc. Natl Acad. Sci. USA101(41), 14937–14942 (2004).
   PubMed Web of Science ®Google Scholar
• Hertz L, Dringen R, Schousboe A, Robinson SR. Astrocytes: glutamate producers for neurons. J. Neurosci. Res.57(4), 417–428 (1999).
   PubMed Web of Science ®Google Scholar
• Anderson C, Swanson R. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia32(1), 1–14 (2000).
   PubMed Web of Science ®Google Scholar
• Pellerin L, Pellegri G, Bittar P et al. Evidence supporting the existence of an activity-dependent astrocyte–neuron lactate shuttle. Dev. Neurosci.20, 291–299 (1998).
   PubMed Web of Science ®Google Scholar
• Kirchhoff F, Dringen R, Giaume C. Pathways of neuron–astrocyte interactions and their possible role in neuroprotection. Eur. Arch. Psychiatry Clin. Neurosci.251(4), 159–169 (2001).
   Google Scholar
• Aschner M. Neuron–astrocyte interactions: implications for cellulalr energetics and antioxidant levels. Neurotoxicology21(6), 1101–1107 (2000).
   PubMed Web of Science ®Google Scholar
• Sagara JI, Miura K, Bannai S. Maintenance of neuronal glutathione by glial cells. J. Neurochem.61(5), 1672–1676 (1993).
   PubMed Web of Science ®Google Scholar
• Dringen R, Gutterer JM, Gros C, Hirrlinger J. Aminopeptidase N mediates the utilization of the GSH precursor CysGly by cultured neurons. J. Neurosci. Res.66(5), 1003–1008 (2001).
   Google Scholar
• Dringen R. Metabolism and functions of glutathione in brain. Prog. Neurobiol.62(6), 649–671 (2000).
   PubMed Web of Science ®Google Scholar
• Deuther-Conrad W, Loske C, Schinzel R, Dringen R, Riederer P, Münch G. Advanced glycation endproducts change glutathione redox status in SH–SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism. Neurosci. Lett.312(1), 29–32 (2001).
   Google Scholar
• Reilly JF, Maher PA, Kumari VG. Regulation of astrocyte GFAP expression by TGF-β1 and FGF-2. Glia22(2), 202–210 (1998).
   PubMed Web of Science ®Google Scholar
• Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci.20(12), 570–577 (1997).
   PubMed Web of Science ®Google Scholar
• Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging21(3), 383–421 (2000).
   PubMed Web of Science ®Google Scholar
• Simpson J, Ince P, Lace G et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol. Aging DOI: 10.1016/j.neurobiolaging.2008.05.015 (2008) (Epub ahead of print).
   Google Scholar
• Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci.18(20), 8126–8132 (1998).
   PubMed Web of Science ®Google Scholar
• Paris D, Townsend KP, Obregon DF, Humphrey J, Mullan M. Pro-inflammatory effect of freshly solubilized β-amyloid peptides in the brain. Prostaglandins Other Lipid Mediat.70(1–2), 1–12 (2002).
   Google Scholar
• Sheng JG, Mrak RE, Griffin WS. Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1α+ microglia and S100β+ astrocytes with neurofibrillary tangle stages. J. Neuropathol. Exp. Neurol.56(3), 285–290 (1997).
   PubMed Web of Science ®Google Scholar
• Ikeda K, Haga C, Akiyama H, Kase K, Iritani S. Coexistence of paired helical filaments and glial filaments in astrocytic processes within ghost tangles. Neurosci. Lett.148(1–2), 126–128 (1992).
   PubMedGoogle Scholar
• Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol.17(4), 359–365 (2005).
   PubMed Web of Science ®Google Scholar
• Bsibsi M, Persoon-Deen C, Verwer RW, Meeuwsen S, Ravid R, Van Noort JM. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia53(7), 688–695 (2006).
   PubMed Web of Science ®Google Scholar
• Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express Toll-like receptors for bacterial products. Glia43(3), 281–291 (2003).
   PubMed Web of Science ®Google Scholar
• Wanner IB, Deik A, Torres M et al. A new in vitro model of the glial scar inhibits axon growth. Glia56(15), 1691–1709 (2008).
   PubMed Web of Science ®Google Scholar
• Pulver M, Carrel S, Mach JP, de Tribolet N. Cultured human fetal astrocytes can be induced by interferon-g to express HLA-DR. J. Neuroimmunol.14(2), 123–133 (1987).
   Google Scholar
• Skias DD, Kim DK, Reder AT, Antel JP, Lancki DW, Fitch FW. Susceptibility of astrocytes to class I MHC antigen-specific cytotoxicity. J. Immunol.138(10), 3254–3258 (1987).
   PubMed Web of Science ®Google Scholar
• Hickey WF, Osborn JP, Kirby WM. Expression of Ia molecules by astrocytes during acute experimental allergic encephalomyelitis in the Lewis rat. Cell. Immunol.91(2), 528–535 (1985).
   PubMed Web of Science ®Google Scholar
• Male DK, Pryce G, Hughes CC. Antigen presentation in brain: MHC induction on brain endothelium and astrocytes compared. Immunology60(3), 453–459 (1987).
   PubMed Web of Science ®Google Scholar
• Grenier Y, Ruijs TC, Robitaille Y, Olivier A, Antel JP. Immunohistochemical studies of adult human glial cells. J. Neuroimmunol.21(2–3), 103–115 (1989).
   PubMed Web of Science ®Google Scholar
• Dong Y, Benveniste EN. Immune function of astrocytes. Glia36(2), 180–190 (2001).
   PubMed Web of Science ®Google Scholar
• Benveniste E. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev.9(3–4), 259–275 (1998).
   PubMed Web of Science ®Google Scholar
• Tuppo E, Arias H. The role of inflammation in Alzheimer’s disease. Int. J. Biochem. Cell Biol.37(2), 289–305 (2005).
   PubMed Web of Science ®Google Scholar
• Dong Y, Benveniste E. Immune function of astrocytes. Glia36(2), 180–190 (2001).
   PubMed Web of Science ®Google Scholar
• Pasternack J, Abraham C, Van Dyke B, Potter H, Younkin S. Astrocytes in Alzheimer’s disease gray matter express a 1-antichymotrypsin mRNA. Am. J. Pathol.135(5), 827–834 (1989).
   PubMed Web of Science ®Google Scholar
• Beach T, McGeer E. Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer’s disease visual cortex. Brain Res.463(2), 357–361 (1988).
   Google Scholar
• Marshak DR, Pesce SA, Stanley LC, Griffin W. Increased S100 b neurotrophic activity in Alzheimer’s disease temporal lobe. Neurobiol. Aging13(1), 1–7 (1992).
   PubMedGoogle Scholar
• Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer’s disease: a progression factor for amyloid-β-induced cellular perturbation? J. Alzheimers Dis.16(4), 833–843 (2009).
   PubMed Web of Science ®Google Scholar
• Wang Z, Li DD, Liang YY, Wang DS, Cai NS. Activation of astrocytes by advanced glycation end products: cytokines induction and nitric oxide release. Acta Pharmacol. Sin.23(11), 974–980 (2002).
   Google Scholar
• Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer’s disease in old age: the role of microglia and astrocytes. Aging Cell3(4), 169–176 (2004).
   PubMed Web of Science ®Google Scholar
• Mrak RE, Sheng JG, Griffin WS. Glial cytokines in Alzheimer’s disease: review and pathogenic implications. Hum. Pathol.26(8), 816–823 (1995).
   PubMed Web of Science ®Google Scholar
• Retz W, Gsell W, Münch G, Rosler M, Riederer P. Free radicals in Alzheimer’s disease. J. Neural Transm. Suppl.54, 221–236 (1998).
   PubMedGoogle Scholar
• McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann. NY Acad. Sci.1035, 104–116 (2004).
   PubMed Web of Science ®Google Scholar
• Simonian N, Coyle J. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol.36(1), 83–106 (1996).
   PubMed Web of Science ®Google Scholar
• Behl C. Alzheimer’s disease and oxidative stress: implications for novel therapeutic approaches. Prog. Neurobiol.57(3), 301–323 (1999).
   PubMed Web of Science ®Google Scholar
• Christen Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr.71(2), S621–S629 (2000).
   PubMed Web of Science ®Google Scholar
• Aksenov M, Aksenova M, Butterfield DA, Markesbery WR. Oxidative modification of creatine kinase BB in Alzheimer’s disease brain. J. Neurochem.74(6), 2520–2527 (2000).
   PubMed Web of Science ®Google Scholar
• Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer’s disease. Neuroscience103(2), 373–383 (2001).
   PubMed Web of Science ®Google Scholar
• Castegna A, Aksenov M, Aksenova M et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med.33(4), 562–571 (2002).
   PubMed Web of Science ®Google Scholar
• Castegna A, Aksenov M, Thongboonkerd V et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyrimidinase-related protein 2, α-enolase and heat shock cognate 71. J. Neurochem.82(6), 1524–1532 (2002).
   PubMed Web of Science ®Google Scholar
• Castegna A, Thongboonkerd V, Klein J, Lynn B, Markesbery W, Butterfield D. Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J. Neurochem.85(6), 1394 (2003).
   PubMed Web of Science ®Google Scholar
• Gow A, Duran D, Malcolm S, Ischiropoulos H. Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett.385(1–2), 63–66 (1996).
   PubMed Web of Science ®Google Scholar
• Sultana R, Poon H, Cai J et al. Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach. Neurobiol. Dis.22(1), 76–87 (2006).
   PubMed Web of Science ®Google Scholar
• Butterfield D, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev.122(9), 945–962 (2001).
   PubMed Web of Science ®Google Scholar
• Butterfield D, Stadtman E. Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol.2, 161–191 (1997).
   Google Scholar
• Lüth HJ, Münch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer’s disease is structurally related to nitrotyrosine formation. Brain Res.953(1–2), 135–143 (2002).
   PubMed Web of Science ®Google Scholar
• Fernandez-Vizarra P, Fernandez A, Castro-Blanco S et al. Expression of nitric oxide system in clinically evaluated cases of Alzheimer’s disease. Neurobiol. Dis.15(2), 287–305 (2004).
   PubMed Web of Science ®Google Scholar
• Pacher P, Beckman J, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev.87(1), 315 (2007).
   PubMed Web of Science ®Google Scholar
• Good P, Werner P, Hsu A, Olanow C, Perl D. Evidence of neuronal oxidative damage in Alzheimer’s disease. Am. J. Pathol.149(1), 21–28 (1996).
   PubMed Web of Science ®Google Scholar
• Vodovotz Y, Lucia M, Flanders K et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer’s disease. J. Exp. Med.184(4), 1425–1433 (1996).
   PubMed Web of Science ®Google Scholar
• Freemantle E, Vandal M, Tremblay-Mercier J et al. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot. Essent. Fatty Acids75(3), 213–220 (2006).
   PubMed Web of Science ®Google Scholar
• Alexander G, Chen K, Pietrini P, Rapopor S, Reiman E. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am. J Psychiatry159(5), 738–745 (2002).
   PubMed Web of Science ®Google Scholar
• Small GW, Ercoli LM, Silverman DH et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc. Natl Acad. Sci. USA97(11), 6037–6042 (2000).
   PubMed Web of Science ®Google Scholar
• Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol.56(8), 901–911 (1997).
   Google Scholar
• Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann. Neurol.40(5), 759–766 (1996).
   PubMed Web of Science ®Google Scholar
• Scott H, Pow D, Tannenberg A, Dodd P. Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer’s disease. J. Neurosci.22(3), RC206 (2002).
   Google Scholar
• Smith GM, Miller RH. Immature type-1 astrocytes suppress glial scar formation, are motile and interact with blood vessels. Brain Res.543(1), 111–122 (1991).
   Google Scholar
• Butterfield DA, Hensley K, Cole P et al. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer’s disease. J. Neurochem.68(6), 2451–2457 (1997).
   PubMed Web of Science ®Google Scholar
• Calabrese V, Sultana R, Scapagnini G et al. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer’s disease. Antioxid. Redox Signal.8, 1975–1986 (2006).
   PubMed Web of Science ®Google Scholar
• Reed T, Perluigi M, Sultana R et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer’s disease. Neurobiol. Dis.30(1), 107–120 (2008).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Radic. Biol. Med.32(11), 1050–1060 (2002).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer’s disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis.12(1), 61–72 (2007).
   PubMed Web of Science ®Google Scholar
• Karelson E, Bogdanovic N, Garlind A et al. The cerebrocortical areas in normal brain aging and in Alzheimer’s disease: noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem. Res.26(4), 353–361 (2001).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Boyd-Kimball D. Proteomics analysis in Alzheimer’s disease: new insights into mechanisms of neurodegeneration. Int. Rev. Neurobiol.61, 159–188 (2004).
   PubMed Web of Science ®Google Scholar
• Newman S, Sultana R, Perluigi M et al. An increase in S-glutathionylated proteins in the Alzheimer’s disease inferior parietal lobule, a proteomics approach. J. Neurosci. Res.85(7), 1506–1514 (2007).
   PubMedGoogle Scholar
• Giustarini D, Rossi R, Milzani A, Colombo R, Dalle-Donne I. S-glutathionylation: from redox regulation of protein functions to human diseases. J. Cell. Mol. Med.8(2), 201–212 (2004).
   PubMed Web of Science ®Google Scholar
• Dalle-Donne I, Milzani A, Gagliano N, Colombo R, Giustarini D, Rossi R. Molecular mechanisms and potential clinical significance of S-glutathionylation. Antioxid. Redox Signal.10(3), 445–473 (2008).
   PubMed Web of Science ®Google Scholar
• Hensley K, Robinson K, Gabbita S, Salsman S, Floyd R. Reactive oxygen species, cell signaling, and cell injury. Free Radic. Biol. Med.28(10), 1456–1462 (2000).
   PubMed Web of Science ®Google Scholar
• Babior B. NADPH oxidase: an update. Blood, 93(5), 1464–1476 (1999).
   PubMed Web of Science ®Google Scholar
• Holland J, O’Donnell R, Chang M, Johnson D, Ziegler L. Endothelial cell oxidant production: effect of NADPH oxidase inhibitors. Endothelium7(2), 109–119 (2000).
   PubMed Web of Science ®Google Scholar
• Pahan K, Sheikh F, Namboodiri A, Singh I. Inhibitors of protein phosphatase 1 and 2A differentially regulate the expression of inducible nitric-oxide synthase in rat astrocytes and macrophages. J. Biol. Chem.273(20), 12219–12226 (1998).
   Google Scholar
• Issels RD, Nagele A, Eckert KG, Wilmanns W. Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine. Biochem. Pharmacol.37(5), 881–888 (1988).
   PubMed Web of Science ®Google Scholar
• Issels RD, Nagele A. Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells. Cancer Res.49(8), 2082–2086 (1989).
   PubMed Web of Science ®Google Scholar
• Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease. Neurology57(8), 1515–1517 (2001).
   PubMed Web of Science ®Google Scholar
• Begni B, Brighina L, Sirtori E et al. Oxidative stress impairs glutamate uptake in fibroblasts from patients with Alzheimer’s disease. Free Radic. Biol. Med.37(6), 892–901 (2004).
   PubMed Web of Science ®Google Scholar